- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Civil Rights and Police Misconduct
- Business Litigation
- Childhood Sexual Abuse Litigation
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Restructuring and Business Bankruptcy
- Wealth Planning, Administration, and Disputes
-
February 20, 2020Robins Kaplan LLP and Partner Hollis Salzman Named Finalists for Global Competition Review’s 2020 Antitrust Awards
-
February 14, 2020Robins Kaplan Recognized in 2020 World Trademark Review 1000
-
February 13, 2020Settlement Announced in Tribal Voting Identification and Ballot Access Case
-
March 2, 2020Conference of Tribal Lending Commissioners
-
March 4, 2020The Women Lawyers Association of Los Angeles 25th Annual Litigators Forum
-
March 4, 2020Women in Legal and Corporate Leadership Summit
-
February 11, 2020INSIGHT: California’s Rebuke of Forced Arbitration in Limbo, Full of Uncertainty
-
February 7, 2020Colossus and Xactimate: A Tale of Two AI Insurance Software Programs
-
February 2020Have You Seen My Genes? Preconception Carrier Screening
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
IP: Generic Manufacturers Win In The Supreme Court
The Supreme Court overruled the Federal Circuit, ruling that generic manufacturers can use counterclaims to force corrections of patent use codes.
July 17, 2012
This spring the Supreme Court seems to have made it easier for generic drug manufacturers to contest the reach of patent protection for brand name drugs. In Caraco Pharmaceutical Labs, Ltd. v. Novo Nordisk, the Supreme Court ruled that a congressionally-created counterclaim allows generic manufacturers to challenge the exact uses a drug patent covers. Generic manufacturers can use the counterclaim in cases where a patent holder asserts infringement in response to an application to manufacture a generic version of a brand-name drug (i.e., Abbreviated New Drug Application or ANDA).
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.
InsideCounsel
Related Professionals
Bryan J. Vogel
Partner
Related Publications
January 10, 2020
September 22, 2019
Weaponizing IPRs
Landslide
August 29, 2019
Resolving Patent Disputes
Financier Worldwide
July 1, 2019
May 20, 2019
Adapt Your IP Strategy for Artificial Intelligence
Robins Kaplan LLP
Related News
September 16, 2019
July 26, 2019
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.